The Renin-Angiotensin System (RAS) is recognized as the main biological system involved in cardiovascular
and hydroelectrolyte homeostasis. It is well established in literature that RAS blockers retard the progression of renal
failure in type 1 [angiotensin converting enzyme (ACE) inhibitors] and in type 2 [angiotensin type 1 receptor (AT1)
antagonists] diabetes mellitus and in non-diabetic chronic kidney diseases. More recently, it was shown that newer
therapeutic agents, the renin inhibitors, also exert renoprotective actions. Obesity is recognized as a proinflammatory state
often associated with kidney diseases. Recent publications have associated the RAS axis imbalance leading to a
predominance of Angiotensin II effects with changes in adipokine levels and actions. In this context, the aim of the
current review is to present current evidence on the potential role of RAS blockers in modulating the interaction between
adipokines and obesity-related renal disorders.
Keywords: Adipokines, angiotensin-(1-7), angiotensin II, chronic kidney disease, inflammation, obesity.
Rights & PermissionsPrintExport